MarizoMib
| CAS No. | 437742-34-2 | Cat. No. | BCP13082 |
| Name | MarizoMib | ||
| Synonyms | ML 858; ML-858; ML858; NPI 0052; NPI-0052; NPI0052; (-)-Salinosporamide A; Salinosporamide A; | ||
| Formula | C15H20ClNO4 | M. Wt | 313.78 |
| Description | Marizomib, also known as ML 858, NPI-0052 and Salinosporamide A, is a potent and selective 20S proteasome inhibitor from natural origin. Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. Marizomib exhibits prolonged inhibition, attenuated efflux, and greater cytotoxicity than its reversible analogs. | ||
| Pathways | Protease/Metabolic Enzyme | ||
| Targets | Proteasome | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.